Doing Business the Japanese Way

Posted:
11
August 2004

Dr Lorch (second from left) and Dr Täubel (third from left) visiting business partners in Japan

Our Managing Director Dr Jörg Täubel and Medical Director Dr Ulrike Lorch recently travelled to Japan to meet with business partners and learn more about the Japanese way of doing business.Nemawashi is a Japanese business process which assures a consensus and harmony between business partners. Nemawashi allows both parties to save valuable time before important meetings because both sides are able to adjust opinions and positions beforehand.

Dr Täubel (second from left) and Dr Lorch (third from left) visiting business partners in Japan

Dr Täubel and Dr Lorch gained first hand experience of Nemawashi during the week-long trip, during which time they met with a range of policy makers, media and business partners to gain further insights into the Japanese CRO and SMO markets.“The trip was a huge success” said Dr Lorch. “Not only did we hold very positive meetings with stakeholders, we also discovered a new and exciting way of life. I have started learning Japanese to help develop relations with our partners in future!”

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.
Read more

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021
Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.
Read more